HEOR

News

NICE says no to Merck Serono's Bavencio in bladder cancer

Merck Serono's Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is to

News

NICE says yes to Novartis' multiple sclerosis therapy Kesimp...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Scotland opens door to Translarna for Duchenne muscular dyst...

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland gave a green light to use of PTC Therapeutics' Translarna for the first time.

News

NICE backs Sobi's Kineret for rare inflammatory disease

The UK's cost-effectiveness agency NICE has recommended that Sobi's Kineret can be used to treat NHS patients with Still's disease, a rare form of arthritis affecting children and adults.

News

Double first for Scotland as it backs Roche’s Rozlytrek, Nov...

The Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment of solid tumours with NTRK gene fusion mutations, regardless of where they o

News

NICE says no to AZ’s Lynparza for prostate cancer

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.

NICE says no to Merck Serono's Bavencio in bladder cancer

NICE says yes to Novartis' multiple sclerosis therapy Kesimp...

Scotland opens door to Translarna for Duchenne muscular dyst...

NICE backs Sobi's Kineret for rare inflammatory disease

Double first for Scotland as it backs Roche’s Rozlytrek, Nov...

NICE says no to AZ’s Lynparza for prostate cancer

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

HEOR

Editor's Picks